Bioactive compounds benet signicantly from PEGylation in both pharmaco­logical and biological applications. The most popular technique for giving drug nanocarriers stealth characteristics is now “PEGylation.” Target-site drug deliv­ery systems are becoming more popular in the pharmaceutical industry because of their many benets, including greater bioavailability and increased drug dos­age capacity. However, specic current issues must be resolved. The interplay between drug delivery systems and blood proteins serves as one example. Based on alterations to the polyethylene glycol surface, this problem has a strong can­didate. The most well-known and complex technique to create drug delivery sys­tems with an extended blood circulation period is the surface coating of different medicinal nanocarriers with polyethylene glycol. For drug-loaded nanocarriers to effectively accumulate in target organs or tissues, prolonged circulation is often necessary. Targeted distribution is made possible by polyethylene glycol’s protection against potential exterior interactions with other chemicals. These innovative methods can help cure diseases like cancer, diabetes, hemophilia, and pain. This research examines key polyethylene glycol and other polymer charac­teristics that can be leveraged to create long-circulating nanocarriers. This review also includes descriptions of PEGylated liposomes, metal nanoparticles, poly-

meric nanoparticles, and other drug delivery systems. This strategy is expected to offer more viable and valuable applications soon.

A peptide, protein, or nonpeptide monomer is modied when one or more polyeth­ylene glycol (PEG) chains are joined. Davies and Abuchowsky initially discussed PEGylation in two critical articles on albumin and catalase modication in the 1970s. This was a signicant turning point since, at the time, it was not thought pos­sible to signicantly alter an enzyme while maintaining its activity. Since proteins were considered susceptible, only a few mild changes with low-molecular-weight products were made, mainly to study structural activity relationships (SARs). Since then, the initially stated PEGylation process has dramatically grown and improved, and various chemical and enzymatic conjugation methods are now available. The range of modication techniques provides the possibility of addressing the needs of various proteins. Only the desired amino acids in the sequence can be modied using a more reactive PEG.The original PEG targets were amino groups via acyla­tion or alkylation reactions. Still, PEG can also be conjugated to thiol, hydroxyl, or amide groups utilizing a variety of specialized chemical or enzymatic techniques. This polymer is safe, immunogenic, and antigenic and has FDA approval. It is also highly soluble in water. The PEG-drug conjugates have many benets, including an extended residence in the body, a reduced rate of metabolic enzyme breakdown, and a decreased or eliminated level of protein immunogenicity (Thakur etal. 2015).

digest PEG 20,000 to create oligomers as metabolic products. Only cyanocobala­min and adenosylcobalamin accelerated the process among the cofactors exam­ined, albeit the effect differed between preparations. These authors evaluated the incubation mixture’s enzyme activity using vapor-phase chromatography. However, measuring chemicals when unknown metabolizable materials are present is dan­gerous. Schöberl was the rst to propose that a C1 step catabolizes PEG, releasing formate, which is metabolized by a serine pathway. He then changed his mind about the C1 theory, noting that dimer–tetramer interactions produced dicarboxy products, showing that an ether bond was broken to release glycolic acid (Kawai

Pharmaceutical formulations for parenteral, topical, ocular, oral, and rectal deliv­ery use PEGs, which have also been explored in controlled-release devices with biodegradable polymeric matrices. Polyethylene glycol mixtures have various advantages over lipids when employed as suppository bases. For instance, the sup­pository’s melting point can be increased to endure exposure to warmer regions. Furthermore, the physical stability of the suppository during storage is improved, the drug’s release is not dependent on the suppository’s melting point, and supposi­tories are readily miscible with rectal uids. It was hypothesized and reported that the dimer tetramer yielded dicarboxy products, indicating that an ether bond was broken to release glycolic acid. The amount of release of drugs that are water sol­uble decreases as the molecular weight of polyethylene glycol increases. Mucous membranes are often more irritated by polyethylene glycols than by lipids (Ciolacu etal. 2020).

PEG 300 and 400 are allowed in parenteral up to 30% v/v. High MW PEGs are frequently utilized to microencapsulate active pharmaceutical ingredients. PEGs reduce the use of strong solvents throughout encapsulation. PEG is a lubricant that is used in eye drops. PEG is a perfect excipient for liquid dosage forms since it resists rancidity and mold growth. PEGs in liquid form (MW up to 1000) are typi­cally utilized as emulsion stabilizers and suspending agents in conjunction with other stabilizers. Additionally, it serves as a solubilizer for liquid-lled soft gelatin capsules or drops (for ophthalmic or otic treatments) (Pham Le Khanh etal. 2022).

The use of micellar solubilization frequently achieves hydrophobic medication solubilization. The surfactant increases the wetting of solids by rst lowering sur­face tension. Micelles then develop above the CMC, encasing the medication and improving its solubilization. PEG and hydrophobic polymers like PLGA, poly amino acids, and PCL can easily self-assemble to generate nanoscale core-shell structures that resemble micellar structures. These nanoscale structures make hydro­phobic moieties, such as those found in medicines, proteins, peptides, and genes, more soluble. It is generally known that macromolecular co-polymers have a critical aggregation concentration (CAC), below which the co-polymers exist as unimers. As the overall concentration increases to a level equivalent to the CAC value, aggre­gates of micellar-like structures begin to grow. Over CAC, they generate micellar structures with a typical core shell. These thermodynamically stable molecules can facilitate the solubilization of hydrophobic medicines. The PEG shell’s presence